PDUFA 2.5?: Delay In FY 2003 FDA Appropriations Has PDUFA III In Limbo
Executive Summary
FDA is stalled in implementing portions of PDUFA III while it awaits Congressional approval of an appropriations bill for FY 2003
You may also be interested in...
FDA Defines Good Review Management; No Data In Labeling Negotiations
Last-minute labeling negotiations are not an appropriate time for presentation of additional data by NDA sponsors, FDA said in a draft guidance on review practices
FDA Defines Good Review Management; No Data In Labeling Negotiations
Last-minute labeling negotiations are not an appropriate time for presentation of additional data by NDA sponsors, FDA said in a draft guidance on review practices
FDA Hormone Therapy Outreach Campaign Urged By Congress In Budget
FDA should do more to communicate information regarding the use of hormone therapy, the fiscal 2003 omnibus appropriations bill urges